- In March 2025, Bayer AG received extended EMA approval for Xarelto (rivaroxaban) in pediatric atrial fibrillation treatment.
- In February 2025, Boehringer Ingelheim launched a post-marketing safety study of dabigatran in elderly AF patients across Germany and Sweden.
- In January 2025, the UK MHRA approved a mobile app linked to NHS electronic prescriptions for DOAC dose reminders.
- In December 2024, Pfizer Inc. and Bristol Myers Squibb expanded their collaborative real-world registry for Eliquis in France and Italy to evaluate bleeding outcomes.
